Related references
Note: Only part of the references are listed.Network-based prediction of drug combinations
Feixiong Cheng et al.
NATURE COMMUNICATIONS (2019)
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations
Hidejiro Torigoe et al.
CANCER SCIENCE (2018)
m6A mRNA methylation sustains Treg suppressive functions
Jiyu Tong et al.
CELL RESEARCH (2018)
Network-based approach to prediction and population-based validation of in silico drug repurposing
Feixiong Cheng et al.
NATURE COMMUNICATIONS (2018)
m6A modulates haematopoietic stem and progenitor cell specification
Chunxia Zhang et al.
NATURE (2017)
Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition
Jianjiao Wang et al.
CELL CYCLE (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Molecular chess? Hallmarks of anti-cancer drug resistance!
Ian A. Cree et al.
BMC CANCER (2017)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Martin Schuler et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
The m6A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells
Shuibin Lin et al.
MOLECULAR CELL (2016)
m6A-LAIC-seq reveals the census and complexity of the m6A epitranscriptome
Benoit Molinie et al.
NATURE METHODS (2016)
Afatinib: A Review in Advanced Non-Small Cell Lung Cancer
Gillian M. Keating
TARGETED ONCOLOGY (2016)
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein et al.
CANCER RESEARCH (2015)
5′ UTR m6A Promotes Cap-Independent Translation
Kate D. Meyer et al.
CELL (2015)
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Xiao Wang et al.
CELL (2015)
A majority of m6A residues are in the last exons, allowing the potential for 3′ UTR regulation
Shengdong Ke et al.
GENES & DEVELOPMENT (2015)
RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation
Yanan Yue et al.
GENES & DEVELOPMENT (2015)
The complex evolution of antibiotic resistance in Mycobacterium tuberculosis
J. D. Fonseca et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Dynamic m6A mRNA methylation directs translational control of heat shock response
Jun Zhou et al.
NATURE (2015)
Gene signatures of drug resistance predict patient survival in colorectal cancer
Y. Zheng et al.
PHARMACOGENOMICS JOURNAL (2015)
Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase
Xiao-Li Ping et al.
CELL RESEARCH (2014)
m6A RNA Modification Controls Cell Fate Transition in Mammalian Embryonic Stem Cells
Pedro J. Batista et al.
CELL STEM CELL (2014)
N6-methyladenosine-dependent regulation of messenger RNA stability
Xiao Wang et al.
NATURE (2014)
N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells
Yang Wang et al.
NATURE CELL BIOLOGY (2014)
A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Jianzhao Liu et al.
NATURE CHEMICAL BIOLOGY (2014)
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer
Sandra Misale et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies
Martina McDermott et al.
FRONTIERS IN ONCOLOGY (2014)
RNA-Methylation-Dependent RNA Processing Controls the Speed of the Circadian Clock
Jean-Michel Fustin et al.
CELL (2013)
Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
Soyeon Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
ALKBH5 Is a Mammalian RNA Demethylase that Impacts RNA Metabolism and Mouse Fertility
Guanqun Zheng et al.
MOLECULAR CELL (2013)
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang et al.
NUCLEIC ACIDS RESEARCH (2013)
Complex environmental drivers of immunity and resistance in malaria mosquitoes
Courtney C. Murdock et al.
PROCEEDINGS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2013)
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dan Dominissini et al.
NATURE (2012)
N6-methyl-adenosine (m6A) in RNA: An Old Modification with A Novel Epigenetic Function
Yamei Niu et al.
GENOMICS PROTEOMICS & BIOINFORMATICS (2012)
Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers
Xiaofei Chang et al.
CANCER RESEARCH (2010)
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sreenath V. Sharma et al.
CELL (2010)
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
Helmout Modjtahedi et al.
ANTI-CANCER DRUGS (2009)
Chemosensitization and Immunosensitization of Resistant Cancer Cells to Apoptosis and Inhibition of Metastasis by the Specific NF-kappa B Inhibitor DHMEQ
Alina Katsman et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Methylation Linear Discriminant Analysis (MLDA) for identifying differentially methylated CpG islands
Wei Dai et al.
BMC BIOINFORMATICS (2008)
Molecular origins of cancer: Lung cancer
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
CpG island methylation of DNA damage response genes in advanced ovarian cancer
JM Teodoridis et al.
CANCER RESEARCH (2005)
Share Paper
